Company intelligence / Profile preview

GlobeImmune

Louisville, Colorado, United Statesglobeimmune.com ↗

Ownership: Public · GBIM
Employees: ~22
Development stage: Phase 2

Overview

The company has two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. GI-6207 and GI-6301 are in clinical trials for various cancers. A hepatitis B product candidate failed clinical trials in 2015.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Therapeutic vaccines (Tarmogens)
Industry: Biotech

Drug pipeline

6 assets

GI-6207

5 more assets in the full pipeline.

Request access →

Partnerships

Celgene (established in 2009)National Cancer InstituteGilead (terminated in November 2016)

Financials

Market cap: $575
Total revenue: $942.8K
Enterprise value: $-8.7M

Beyond the preview

Go deeper on GlobeImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlobeImmune.

Explore the full profile